Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (RECORD 4)

Share this article:
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (RECORD 4)

Sponsors and Collaborators
Novartis Pharmaceuticals

Contact
Novartis Pharmaceuticals
+1-862-778-8300

Principal Investigator
Novartis Pharmaceuticals

ClinicalTrials.gov Identifier
NCT01491672

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions